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Abstract 
Postpartum haemorrhage (PPH) is the leading cause of maternal mortality and morbidity globally. 
Obstetric bleeding can be catastrophic and management is challenging, involving a coordinated 
multidisciplinary approach, which may include blood products. In settings where blood transfusion is 
not an option, either because of patient refusal (most commonly in Jehovah Witnesses) or because 
of unavailability of blood, management becomes even more challenging. Observational studies have 
demonstrated an association between refusal of blood products in major obstetric haemorrhage and 
increased morbidity and mortality. This review draws upon evidence in the literature, physiological 
principles and expert opinion for strategies and guidance to optimise the outcomes of pregnant 
women in whom blood transfusion is either refused or impossible. The importance of a 
multidisciplinary antenatal and perinatal management plan, including optimisation of haemoglobin 
and iron stores pre-delivery, blood loss minimisation, early haemorrhage control and postpartum 
anaemia treatment, is discussed. 
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Introduction  
While transfusion may play an important role in optimising maternal and fetal outcomes in 
pregnancy, there are some situations where the administration of blood or blood products is not a 
therapeutic option. This can arise where a patient has complex red cell antibodies or a rare blood 
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group, because blood products are unavailable or because the woman concerned refuses 
transfusion for religious or other reasons. Irrespective of the reason why transfusion is not possible, 
it is critically important that these women receive optimal management. Unfortunately, there is an 
association between refusal of blood products and both increased morbidity and mortality in major 
obstetric haemorrhage and substandard clinical care1 with failure to utilise proven interventions that 
may improve outcomes2. This review aims to assist clinicians to develop a pragmatic approach to 
guide their clinical practice and to facilitate pre-emptive measures to minimise morbidity and 
mortality including the optimisation of antenatal haemoglobin, the development of a clear plan for 
labour and birth to minimise blood loss and the adoption of strategies to secure haemostasis 
following haemorrhage, with early recourse to definitive surgery where indicated. 
 
Methods, Scope, Evidence and Limitations 
Good quality evidence to inform management of pregnancy where transfusion is not an option is 
generally lacking. Small numbers of patients, geographical, cultural and political differences, clinical 
and haematological heterogeneity, and ethical principles preclude against level 1 or 2 evidence,  so 
most data is drawn from cohort studies, cross-sectional studies, case series and case reports, as well 
as from physiological principles and expert opinions3,4. While this may limit the strength of any 
generalisations that can be drawn from the literature, these recommendations aim to provide a 
framework for the provision of optimal obstetric care in this challenging circumstance.  
 
Clinical, ethical and legal context 
In pregnancy, bleeding can be unexpected, rapid and massive. In the usual situation, packed red cells 
are given to correct hypovolaemia, shock and oxygen delivery, and platelet transfusions and fresh 
frozen plasma to correct platelet dysfunction, thrombocytopenia and coagulopathy. In some 
situations, however, transfusion may not be possible, either because patients have rare blood 
groups or complex antibodies, or, more commonly, where patients refuse transfusion of blood 
products for personal or religious reasons. Many such patients have uneventful pregnancies, 
however two observational studies from high-risk obstetric units suggests that refusal of transfusion 
in major postpartum haemorrhage may be associated with a much higher risk of mortality (up to 44-
65 times higher) compared to the general obstetric population1,3,5. 
 
While patients with rare blood groups or complex antibodies will still be able to receive platelets and 
fresh frozen plasma, the management of patients refusing blood products is more complex due to 
fewer appropriate therapeutic options. Most commonly this occurs in women who are Jehovah’s 
Witnesses. 
 
The Jehovah’s Witnesses are a Christian religious group founded in the 1870s, with over 7 million 
worldwide, who believe the transfusion of blood products is prohibited by the bible (Genesis 9:3-4; 
Leviticus 17:13-14 and Acts 15:19-21). Jehovah’s Witnesses commonly divide blood products into 
two main groups: products that they will not accept – such as whole blood, red cells, plasma, 
platelets or white cells; and those decided upon by each person’s individual conscience – such as 
immunoglobulins, coagulation-factor preparations, albumin, vaccines and solid organs (Table 1). 
Additionally, Jehovah’s Witnesses generally do not accept pre- and intra-operative storage of blood 
for later autologous transfusion, but individuals may decide personally to accept haemodilution, 
haemodialysis, plasmapheresis, heart-lung bypass and blood salvaging techniques, provided that 
there is continuous extracorporeal circulation. The use of erythropoiesis stimulators and non-blood 
plasma expanders are generally accepted6.  
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Table 1. Products and Procedures to clarify with woman antenatally 
Product or Procedure Detail Usual Jehovah’s Witness 
stance 
Major blood components Red blood cells  
Platelets  
Fresh frozen plasma  
White blood cells 
Refusal 
Blood fractions Cryoprecipitate  
Albumin  
Prothrombinex  
Biostate 
Fibrinogen concentrate 
Individual decision 
RhD Immunoglobulin (Anti-D) Processed from Human Blood Donors Individual decision 
Autologous blood donation Own blood stored Refusal 
Recombinant products Epoetin, Darbepoietin (ESAs) 
Recombinant Factor 7 
Usually accept 
Intra-operative measures Intra-operative blood salvage 
Acute normovolaemic haemodilution 
Individual decision 
Measures to treat complications Haemodialysis Individual decision 
 
Conflict between women who are Jehovah’s Witnesses and health staff sometimes occurs when the 
healthcare team believes that the woman’s best interests, and/or those of her fetus/child are served 
by blood transfusion but the patient refuses. Although health professionals may disagree with such 
refusals, it is generally accepted both that competent patients have the right to refuse any form of 
life-sustaining treatment and that health professionals have a continuing duty to provide care. 
Health professionals can only refuse to provide care where this decision does not adversely impact 
upon the woman’s health and where an alternative caregiver has agreed to accept responsibility for 
ongoing care6,7,8.  
While some doubts have been recently shed on the rights of pregnant women to refuse treatment in 
Australia, the overwhelming preponderance of authority is in favour of a pregnant woman’s right to 
refuse treatment (Box 1). Irrespective of whether a decision to refuse blood products is made 
contemporaneously or in advance – the responsible health care professionals must satisfy 
themselves that the refusal of or consent to blood transfusion is valid, ie that the patient is 
competent to make decisions regarding their care, and that their decision is made freely and 
voluntarily and that the decision clearly applies to the circumstances that have arisen. Where the 
patient is not competent, it is important to establish whether the patient has left a clear record of 
instructions regarding their wishes regarding treatment for when they lack capacity (an advance 
directive or advance care plan). It is also important to establish who is authorised to make decisions 
for them in such situations. Different jurisdictions in Australia and New Zealand recognise different 
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kinds of advance care directives (Table 2) and substitute decision-makers (Table 3).  In all situations 
the patient’s preferences and the details of the consent process should be carefully documented, in 
accordance with local legal requirements. Some institutions may provide an institution specific 
consent form to unambiguously clarify which products and procedures are acceptable (Table 1) to 
the individual. 
Box 1. Cases on the right to refuse treatment  
1. In St George’s Healthcare NHS Trust v S [1998] 3 All ER 673 a pregnant woman refused a caesarean section when 
she was suffering from pre-eclampsia. After refusing treatment she was declared mentally ill by staff and detained. 
The hospital sought a court order authorising treatment but misinformed the trial judge and the patient and her 
solicitors were not informed of the hearing. After receiving the court order and performing the operation, the hospital 
released her. On appeal, the Court of Appeal found that the unborn child’s need for medical attention could not over-
ride the patient’s express and competent refusal. Even where the interference with the woman’s body is minor and 
the refusal of treatment unreasonable, the court will not sanction treatment because the promotion of the woman’s 
autonomy is paramount. 
2. In Hunter and New England Area Health Service v A [2009] NSWSC 761. Mr A was a Jehovah’s Witness who had 
completed an advance directive in which he had indicated his wish not to be given kidney dialysis. In June 2009 A 
was admitted to the hospital suffering septic shock. His kidneys failed and he was being kept alive on a ventilator and 
dialysis machine. McDougall J upheld A’s right to refuse treatment and found that even though there was no express 
provisions for advance directives in Guardianship Act 1987 (NSW), s 33 of the Act recognised the importance of the 
patient’s previously express decisions regarding treatment. Nor was it necessary for health professionals to have to 
advise patients before they could refuse treatment. However McDougall J did mention in passing that there had been 
occasions when the right to refuse treatment might be denied if it lead to death of a viable foetus but he did not refer 
to the case of St George’s Healthcare NHS Trust discussed above. 
3. In X v The Sydney Children's Hospitals Network [2013] NSWCA 320 a mentally competent, Jehovah’s Witness who 
was 17 years and 8 months old, refused blood and platelet transfusions which were a necessary part of his treatment 
for Hodgkin's disease. The patient was suffering severe anaemia but refused to be treated with blood or platelets. 
The Court of Appeal ordered treatment to go ahead arguing that children do not have the right to refuse treatment 
which is in their best interests. 
4. In Re JS [2014] NSWSC 302 the patient was 27 years of age and had been a ventilator dependent quadriplegic since 
the age of seven. JS decided that he no longer wanted to be treated and made an advance directive refusing 
treatment to take effect on his twenty-eighth birthday. The court upheld JS’s decision. 
From a medical perspective, given that it is legally and ethically possible for a woman to refuse blood 
product support during pregnancy, it is even more important that a patient’s wishes regarding 
transfusion are identified early so that clear strategies to reduce anaemia and bleeding can be 
developed that are acceptable to the patient, optimise obstetric care and improve maternal and 
fetal outcomes1.  
Table 2.  Australian and New Zealand legislation on advance care directives 
 Legislation 
ACT Medical Treatment (Health Directions) Act 2006  
NSW No legislation – common law applies 
Qld Powers of Attorney Act 1998 
SA Advance Care Directives Act 2013 
Vic Medical Treatment Act 1988 
WA Guardianship and Administration Act 1990  
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NT Natural Death Act 1988 
NZ Code of Health and Disability Services Consumer’s Rights  
 
Table 3. Substitute decision-makers and their powers to make end-of-life decisions  
 SDM Substitute decision-makers and their powers to make end-of-life decisions   
ACT Guardians   Appointed by the Supreme Court or ACAT 
 Have the power to consent to medical procedures but they do not have an express power to 
refuse treatment: Guardianship and Management of Property Act 1991, s 7. Arguably, 
guardians can refuse treatment in the same as way they can in NSW.  
 Enduring 
attorneys  
 Appointed by the patient in writing 
 Have the power to make decisions to withhold or withdraw medical treatment, if it can be said 
on reasonable grounds that the patient would have made the decision to refuse treatment had 
they been able to make a rational and considered judgment: Powers of Attorney Act 2006, ss 
12, 42(2)(b)  
 Must consult with a doctor regarding the patient’s condition and treatment options prior to 
refusing treatment: s Powers of Attorney Act 2006, 46(2)(a) 
 Health 
attorneys 
Automatically allocated in the absence of a formal appointment to spouse or domestic 
partners, carers or close friends and relatives 
Have the power to consent to treatment but should they refuse to consent the matter must be 
referred to the Public Advocate: Guardianship and Management of Property Act 1991, s 32H.  
Arguably this requires refusals of treatment to be reviewed by the Public Advocate, although it 
would seem unlikely that the Public Advocate would become involved in cases where the 
treating team and health attorney agree that treatment should be limited.  
Cases of dispute should be referred to the ACAT or to the Supreme Court 
NSW Guardians Appointed by the Supreme Court or NCAT 
Have the power to refuse treatment if they have been granted a plenary power, healthcare 
function or a specific power to consent to treatment being withdrawn or withheld: FI v Public 
Guardian [2008] NSWADT 263 
 Enduring 
Guardians 
Appointed by the patient in writing 
Have the power to refuse treatment if they have been granted a plenary power, healthcare 
function or a specific power to consent to treatment being withdrawn or withheld in the 
instrument of their appointment: FI v Public Guardian [2008] NSWADT 263. 
 Persons 
responsible 
Includes guardians and enduring guardians but also spouses, carers and friends and relatives 
who have not been formally appointed  
Persons responsible who have not been formally appointed as guardians or enduring guardians 
are unlikely to be able to refuse treatment as they must consent to treatments which “promote 
and maintain health and wellbeing”: Guardianship Act 1987.  A decision to withhold treatment 
does not appear to fall within the Guardianship Act with deals with treatment provisions not 
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treatment limitation: FI v Public Guardian [2008] NSWADT 263 
Arguably, If there is no guardian, the treatment team and substitute decision-makers may 
agree to withhold/withdraw treatment in the patient’s best interests. In cases of conflict, resort 
should be had to the NCAT or Supreme Court to seek advice. 
NT Guardians Appointed by the courts  
Guardians are given plenary powers as if they were the parent of the patient and may consent 
to treatment in the patient’s best interests: Adult Guardianship Act s 17. Arguably this includes 
end-of-life functions as parents can make end-of-life decisions for children: Re Baby D (No 2) 
[2011] FamCA 176. 
NT does not have legislation allowing enduring powers of attorney or persons responsible. 
Decisions to limit treatment would presumably be made by the treatment team based on an 
assessment of the patient’s best interests. That assessment should ordinarily include 
consultation with the patient’s family/friends: Inquest into the death of Paulo Melo [2008] 
NTMC 080; Melo v Superintendent of Royal Darwin Hospital [2007] NTSC 71 
QLD Guardians Appointed by the Supreme Court or QCAT 
Guardians have clear powers to withhold and withdrawal life sustaining treatments: 
Guardianship & Administration Act 2000, Sch 2, s 5 
 Enduring 
attorneys 
Appointed by the patient in writing 
Have power to make decisions to withhold or withdrawal medical treatment: Powers of 
Attorney Act 1998, Sch 2.   
A decision makers to withdraw or withhold life sustaining treatment will not be effective unless 
continued  
treatment is “inconsistent with good medical practice”: Guardianship and Administration Act 
2000, s 66A.  This would not apply to decisions to refuse blood transfusions as they are not 
defined to be a ‘life-sustaining measure.’ 
 Statutory 
health 
attorneys 
Automatically allocated in the absence of a formal appointment to spouse, carer, close friend 
or relation 
Have the power to refuse treatment: Powers of Attorney Act 1998, Sch 2.  
Healthcare professionals must seek consent from these decision-makers to limit ‘life sustaining 
measure’ but this term  does not include blood transfusions. 
A decision by substitute decision-makers to withdraw or withhold treatment will not be 
effective unless continued  
treatment is “inconsistent with good medical practice”: Guardianship and Administration Act 
2000, s 66A.  This would not apply to decisions to refuse blood transfusions as they are not 
defined to be a ‘life-sustaining measure’ 
In cases of conflict, the Public Advocate automatically is appointed as the substitute decision-
maker. Alternatively, orders can be sought from the QCAT or Supreme Court. 
SA Guardians Appointed by the Supreme Court or Guardianship Board 
Guardians are given plenary powers at law and in equity: Guardianship and Administration Act 
1993, s31. Arguably this includes powers to refuse treatment. 
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 Substitute 
decision-
makers 
Appointed via an ‘advance directive’ completed by the patient 
Have the power to consent to the withholding or withdrawal of treatment: Advance Care 
Directives Act 2013, s 22. They cannot refuse the administration of drugs to relieve pain or 
distress or the natural provision of food and liquids by mouth: s 23. 
 Persons 
responsible 
Automatically allocated in the absence of a formal appointment of a guardian or substitute 
decision-maker 
Persons responsible include a spouse or domestic partner, an adult relate by blood or marriage, 
an adult related by adoption or an adult related by indigenous kinship, a parent (including 
adoptive parents and people in loco parentis, adult friends and an adult in charge of the day to 
day supervision, care and well being of the patient 
Persons responsible can refuse treatment but their decisions must “reflect the decision that the 
patient would have made in the circumstances had his or her decision-making capacity not 
been impaired”: Guardianship and Administration Act 1993, s 14C.  
TAS Guardians Appointed by Supreme Court or Guardianship Board 
Guardians are given plenary powers as if they were the parent of the patient and may consent 
to or refuse treatment in the patient’s best interests: Guardianship and Administration Act 
1995, s 25(2)(e).  Arguably this includes end-of-life functions as parents can make end-of-life 
decisions for children: Re Baby D (No 2) [2011] FamCA 176. 
 Enduring 
Guardians 
Appointed by the patient in writing 
Enduring guardians can also be appointed and will have the same functions as plenary 
guardians , subject to any lawful directions in the instrument: Guardianship and Administration 
Act 1995, s 32(5) 
 Persons 
responsible 
Includes guardians and enduring guardians but also spouses, carers and friends and relatives 
who have not been formally appointed 
Persons responsible who are also not guardians or enduring guardians may consent to 
treatment but there is no express power to refuse treatment: Guardianship and Administration 
Act 1995, s 39. 
Arguably the position is the same as NSW. If the treatment team and substitute decision-
makers agree to withhold/withdraw dialysis in the patient’s best interests then arguably there 
are no legal barriers to doing so. In cases of conflict, resort should be had to the Guardianship 
Tribunal or Supreme Court to seek advice. 
VIC Guardians Appointed but the Supreme Court or VCAT 
Guardians may refuse consent to treatment when it is not in the patient’s best interests: 
Guardianship and Administration Act 1986, s 42H.  
Guardians can also execute a refusal of treatment certificate under the Medical Treatment Act 
1986 when: 
(a) the medical treatment would cause unreasonable distress to the 
patient; or 
(b) there are reasonable grounds for believing that the patient, if 
competent, and after giving serious consideration to his or her health and 
well-being, would consider that the medical treatment is unwarranted. 
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 Enduring 
guardians 
Enduring guardians can be appointed by patients: Guardianship and Administration Act 1986. If 
the instrument is silent on consent issues, the enduring guardian may consent to treatment in 
the patient’s best interests. 
 Medical 
Agents 
Appointed by patients via an enduring power of attorney (medical treatment) 
Medical Agents may employ a refusal of treatment certificate under the Medical Treatment Act 
1986. Medical agents can only execute a refusal of treatment certificate (under s 5B) when: 
(c) the medical treatment would cause unreasonable distress to the 
patient; or 
(d) there are reasonable grounds for believing that the patient, if 
competent, and after giving serious consideration to his or her health and 
well-being, would consider that the medical treatment is unwarranted. 
 Persons 
responsible 
Includes guardians and enduring guardians but also spouses and domestic partners, carers and 
nearest relatives who have not been formally appointed 
Arguably persons responsible (who are not guardians or enduring guardians) can refuse 
consent when it is in the patient’s best interests: Guardianship and Administration Act 1986, s 
42H.  
However, they are not permitted under the Medical Treatment Act to issue a refusal of 
treatment certificate. 
WA Guardians  Appointed but the Supreme Court or WASAT 
 Guardians are given plenary powers as if they were the parent of the patient and may consent 
to or refuse treatment in the patient’s best interests: Guardianship and Administration Act 
1990, ss 45, 110ZJ. 
 Enduring 
guardians 
Appointed by the patient in writing 
Enduring guardians can also be appointed and will have the same powers as plenary guardians, 
subject to any lawful directions in the instrument: Guardianship and Administration Act 1990, s 
110ZJ. 
 Persons 
responsible 
Persons responsible (spouse, carer, close friend or relative) may make treatment decisions 
which include decisions to consent or refuse consent to a treatment: Guardianship and 
Administration Act 1990, s 3. 
NZ Welfare 
guardian 
Appointed by the High Court or Family Court 
Welfare guardians are expressly forbidden from refusing ‘standard treatments’ to preserve life 
or prevent serious damage to the patient’s health: Protection of Personal and Property Rights 
Act 1988: s 18(1)(c) 
 Powers of 
attorney over 
personal care 
and welfare 
Appointed by the patient 
Attorneys are expressly forbidden from refusing ‘standard treatments’ to preserve life or 
prevent serious damage to the patient’s health: Protection of Personal and Property Rights Act 
1988: s 98(4) 
 
 
Recommendations 
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Antenatal Management 
1. Identify patients 
At the first antenatal visit, every woman should be asked whether she would accept or reject blood 
products, if required, during her pregnancy or following delivery. Refusal should be documented in 
the hospital record and patient held card where used, and the woman referred for discussion with a 
consultant obstetrician. Routine antenatal group and screen should identify most patients with 
complex red cell antibodies, and these women should be referred to a haematologist.  
 
2. Discuss and Clarify Blood Product Options 
The clinical focus is on the haemoglobin and bleeding risk – the higher the haemoglobin, the lower 
the risk of severe anaemia; the lower the haemoglobin, the fewer the choices in terms of risk 
minimisation and management.  The aims are to maximise the haemoglobin, to establish a clear plan 
for managing pregnancy, labour and birth, minimising blood loss, and to establish explicit strategies 
for managing haemorrhage, including early stabilisation and referral for surgical intervention as 
indicated. Each of these goals can only be achieved by early and clear communication throughout 
the antenatal and postnatal period involving the patient, their family and the multidisciplinary care 
team – including obstetric, midwifery, anaesthetic and haematology staff.  Ideally the medical staff 
should be senior clinicians with experience in this area. The patient must be counselled about the 
potential catastrophic nature of post-partum haemorrhage and the subsequent increased risk of 
morbidity and mortality, and possible strategies to decrease this. Specifically, the patient must be 
advised that the inability to administer blood products may increase her risk of death or disability 
following major haemorrhage and that even with optimal prenatal care and the implementation of 
non-blood management strategies these risks remain.  
Following discussion it is important to clearly document in the patient record and/or antenatal card 
a summary of the issues discussed; a summary of the products and interventions that are acceptable 
(Table 1); and the details regarding the patient’s advance care plan and/or substitute decision-
maker. If copies of the patient’s advance care plan and appointment of a substitute decision-maker 
is available this should also be filed in the patient record. Contact with the local hospital Jehovah’s 
Witness Liaison Officer is recommended. 
 
Figure 1 Algorithm for managing women in pregnancy for whom transfusion is not an option 
 
1. Identify patients  
 Ask all patients 
 Document 
2. Early pregnancy visit with senior clinician (usually consultant obstetrician) 
 Discuss and document which blood products are acceptable 
 Decide on model of care 
 Decide on planned location of delivery 
 Develop and implement a plan for optimising Hb through pregnancy 
 Ask patient to write detailed legally binding advanced care directive, where needed 
3. Mid pregnancy visit with senior clinician 
 Review blood results and need for additional therapy 
 Review advanced care directive and discuss with patient 
 Organise anaesthetic review 
 Organise haematology review 
4. Late pregnancy visit with senior clinician 
 Review risk factors for PPH 
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 Re-consider location of birth 
 In very high risk cases consider review by gynae- oncology or interventional radiology 
 Document clear intrapartum and postpartum care plan 
5. Management in labour  
 Alert clinicians, iv access 
 Active management of 3
rd
 stage of labour, monitor closely for blood loss 
6. Management of active haemorrhage 
 Involve consultants 
 Early definitive management (*see text) 
 Communication between team members, record losses 
7. Management of Postpartum Anaemia 
 Optimise haematinic status & oxygenation, minimise venesection 
 Consider iv iron + ESA 
 
3. Consultant led care  
Senior medical staff should be part of the antenatal multi-disciplinary management team, which 
should be led by the patient’s obstetrician and include a haematologist and anaesthetist. In selected 
cases, the opinion of an interventional radiologist may need to be sought. Where antenatal care is 
midwifery led, frequent consultation with an obstetrician is advisable and the development of any 
risk factors should prompt timely referral for senior medical review. 
 
4. Assess optimal location for delivery  
Some maternity services may decide to refer these women to higher level facilities depending on 
their service capability. Delivery in a facility unable to perform hysterectomy may be inadvisable in 
some cases. If an institution is unable to provide the potential level of care required in case of 
massive haemorrhage, the patient’s care should generally be transferred to a higher level obstetric 
unit. A Level 4 or higher obstetric unit would generally be recommended for women at standard risk. 
Women at high risk (eg placenta previa) should be referred to a tertiary facility in early pregnancy 
for pregnancy planning and delivery. 
 
5. Minimise other causes of anaemia and blood loss  
 A. Optimise haemoglobin, iron, B12 and iron stores 
The haemoglobin and ferritin should be monitored regularly, at least at booking, 28 and 36 weeks 
gestation. Folate and B12 levels should be assessed at booking. Haematinic deficiency should be 
aggressively replaced. We would recommend all women receive iron (100-200mg elemental 
iron/day) and folate (0.5mg daily), with a target ferritin of 100ug/L9. Intravenous iron should be used 
if oral iron therapy is ineffective or if the woman is intolerant of oral iron. It must be recognised that 
iron deficiency can be present with a normal haemoglobin and that adequate reserves of iron, B12 
and folate are particularly important for women who are unable to be transfused as they are 
required for erythropoiesis, which will be relied on in the event of haemorrhage. 
 B. Minimise blood loss 
Reduce iatrogenic blood loss antenatally with a restrictive phlebotomy approach. 
 C. Anti-platelet and anti-coagulant drugs 
Anti-platelet and anti-coagulant drugs (e.g. aspirin, enoxaparin) should be withheld for the 
appropriate time prior to delivery. The data on the role of erythropoiesis-stimulating agents (ESAs), 
such as epoetin and darbepoietin, in this setting is limited and uncertain (see below). 
 
6. Assess for higher risk of post-partum haemorrhage (PPH)  
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Risk factors for PPH should be assessed in the third trimester (Table 4)10. The mode of delivery 
should be dictated according to conventional obstetric standards: spontaneous labour and normal 
vaginal delivery is preferred, and interventions discouraged unless indicated. A final discussion with 
the woman should include the measures that may be required in case of severe post-partum 
haemorrhage, including post-delivery hysterectomy. In very high risk cases planning should include 
consideration of cell-salvage and placement of percutaneous balloon catheter in iliac arteries pre-
delivery in a facility with these services, following consultation with anaesthetics and interventional 
radiology. 
 
Table 4. Factors to consider in assessing Post-Partum Haemorrhage risk 
Previous pregnancy complications Previous Caesarian section, esp with anterior 
placenta 
Previous PPH 
Previous precipitate labour 
Placentation Placenta praevia 
Placenta accreta 
Uterine tone Multiple pregnancy 
Polyhydramnios 
Macrosomia 
Medical comorbidities Diabetes 
Coagulopathy 
Personal & family bleeding history 
Uncorrectable anaemia 
 
 
Management in Labour 
When a woman in whom transfusion is not an option presents in labour, the Advance Care Plan and 
blood management plan should be reviewed. The senior obstetrician, anaesthetist and 
haematologist should be informed when the woman has been admitted in labour. The minimisation 
of risk factors for PPH, including length of labour, should be considered in intrapartum management. 
A large bore cannula should be placed if there is a high risk of haemorrhage. 
 
Active management of the 3rd stage of labour is generally advised, with rapid stepwise management 
of third stage complications. Following delivery, ensure careful and regular monitoring of vital signs, 
fundal height and blood loss, with accurate documentation of cumulative blood loss. 
 
Management of Active Haemorrhage 
Early definitive management may be life-saving, because blood products will not be available to 
assist in optimising oxygen delivery, cardiac output and haemostasis. Involve the consultant 
obstetrician, anaesthetist and haematologist early. The decision to take the patient to theatre for 
definitive management should generally be made earlier than usual. To arrest significant 
haemorrhage, the definitive procedure is generally hysterectomy. 
 
Obtain haemostasis as quickly as possible. Activate local postpartum haemorrhage protocols with 
rapid progression to the next intervention if haemorrhage is not controlled. 
 
Record ongoing losses in a systematic way to enable recognition and early response.  Ensure clear 
documentation and handover, especially if the patient moves between delivery suite, operating 
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theatres and intensive care. Slow but persistent blood loss requires prompt action and should not be 
ignored. 
 
Early Definitive Management 
1. Operative management: intrauterine balloon tamponade, B Lynch uterine brace suture, 
Subtotal Hysterectomy, bilateral ligation of the uterine arteries and embolisation. 
  2. Cell salvage, if available and acceptable to the woman. 
 3. Pharmacologic agents, including tranexamic acid, recombinant factor VIIa and topical 
haemostatic agents (Tisseel). 
 4. Cryoprecipitate, fibrinogen concentrate or prothrombin complex concentrate if available 
and acceptable to the woman. 
 
Management of Postpartum Anaemia 
Haematinic status should be optimised with intravenous iron, Vitamin B12 and folic acid. Phlebotomy 
should be minimised to reduce ongoing losses – reduce tests ordered and use paediatric sample 
tubes where possible. In severe acute postpartum anaemia consider intravenous iron ± ESA. The use 
of hyperbaric oxygen therapy and synthetic oxygen carriers are controversial and may be considered 
on a case-by-case basis. In the case of severe acute postpartum anaemia (Hb <70g/L), management 
should be guided by early and ongoing expert advice. 
 
*Further Notes: practical advice, evidence and uncertainties 
1. Postpartum intravenous iron 
Studies with various intravenous formulations of iron demonstrate a faster rise in haemoglobin from 
baseline but a similar endpoint, compared to fully compliant oral iron in postpartum iron deficiency 
anaemia11,12,13,14. Modern intravenous formulations have an acceptable adverse risk profile. In 
general it should be assumed that women with moderate postpartum anaemia following PPH have a 
significant iron deficit and would benefit from iron replacement. The choice of iron formulation 
depends on the severity of anaemia, the desired rate of rise in the haemoglobin and the safety of 
the iron formulation.  
 
2. Erythropoiesis-stimulating agents (ESAs): erythropoietin, darbepoetin 
There is no role for routine ESA use, but they may be considered in high risk patients. While the data 
is conflicting, case reports document survival in JW patients with extremely low Hb levels (down to 
10 g/L) with aggressive use of ESAs and/or other supportive measures15,16. The use of ESAs are at the 
discretion of the local unit, requiring local hospital drug committee authorisation and informed 
consent explaining the risks of hypertension and thrombosis. If an ESA is used, it should be combined 
with appropriate iron therapy. 
 
3. Tranexamic acid 
There is strong evidence supporting the use of tranexamic acid in bleeding surgical and trauma 
patients17,18. Interestingly, these studies also show a reduction in thrombotic complications. Several 
randomised control trials have been conducted in the maternity setting and its early use (within 3 
hours of haemorrhage onset) may be of benefit in PPH19.  
 
4. Cryoprecipitate and fibrinogen concentrate 
Recent reviews and case reports have proposed the supplementation of fibrinogen in the setting of 
ongoing bleeding. In Australia this is most commonly achieved with cryoprecipitate. If the patient 
consents to this blood product, it should be considered in the context of ongoing bleeding.  
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Case reports using fibrinogen concentrate during obstetric bleeding have been published. However, 
it is not currently licensed in Australia for obstetric haemorrhage and use in this context would be 
considered “off label.”  
 
5. Intraoperative cell salvage 
Recent studies demonstrate safety of cell salvage in the obstetric setting, despite historical concerns 
for potential amniotic fluid embolism. If acceptable to the patient, its use should be pre-empted19.    
 
6. Intrauterine balloon tamponade 
The use of this technique is becoming increasingly popular. Expulsion of the balloon can be 
prevented by vaginal packing20, although this may conceal continuing bleeding around the balloon.  
If the balloon does not control haemorrhage or is repeatedly expelled it should be abandoned. To 
minimise bleeding risk during removal, use graduated deflation - observing for bleeding – with 
reinflation if bleeding recommences. 
 
7. Subtotal hysterectomy 
Recommendations are for two consultant obstetricians to be present where practical3, to avoid 
hypothermia which would exacerbate coagulopathy (use fluid warmer, BairTM hugger or similar) and 
have cell salvage available. A subtotal procedure may be quicker than total hysterectomy; however 
the choice of procedure is by surgeon preference. A subtotal procedure may also fail to arrest 
haemorrhage from the lower segment in the case of placenta previa or morbidly adherent placenta. 
 
8. Hyperbaric oxygen 
Although rarely used, there are several successful case reports on the use of hyperbaric oxygen in 
severe blood loss anaemia21. Presumably this therapy increases oxygen delivery to the tissues and 
may inhibit inflammatory cytokines. Appropriate patients need to be relatively stable and could be 
discussed with the local Hyperbaric Oxygen therapy unit. 
 
9. Fibrin sealant: Tisseel 
Tisseel is a fibrant sealant available in Australia. Fibrinogen and Thrombin are combined just prior to 
application to generate fibrin. It is TGA approved but not on the PBS. There are no randomised 
control trials (RCTs) in this population. It must be applied topically with potential adverse risks of 
anaphylaxis and systemic thromboembolism. Tisseel includes derivatives of human blood products 
and so may not be acceptable to some patients22.  
 
10. Aprotinin is not available in Australia. 
 
11. Haemoglobin-based oxygen carriers (HBOCs) 
Haemoglobin-based oxygen carriers (synthetic blood) are not currently available in Australia. The 
FDA in USA has suspended trials due to adverse risk profile23.  A large meta-analysis (n=3711) 
demonstrates increased mortality and morbidity with the use of HBOCs in RCTs24. The ‘positive’ 
studies are generally case reports25,26. But while there is little evidence to support their use, we 
acknowledge the difficultly of definitively arguing against their use when all other measures have 
failed, where death may be imminent and where the patient, or their substitute decision-maker has 
given consent to their use.  
 
Conclusion 
Pregnancy and delivery are normal physiological processes which can have catastrophic outcomes in 
specific settings. Where a woman is unwilling or unable to be transfused, the health care team must 
work collaboratively with the patient to reduce morbidity and mortality. These guidelines provide 
direction to optimise materno-fetal outcomes in situations where transfusion is not an option.   
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